Perjeta Approval History 
- FDA approved: Yes (First approved June 8th, 2012)
- Brand name: Perjeta
- Generic name: pertuzumab
- Company: Genentech
- Treatment for: Breast Cancer
Perjeta (pertuzumab) is a humanized monoclonal antibody indicated in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for the treatment of HER2-positive metastatic breast cancer.
FDA Approval History for Perjeta
See also...
Perjeta (pertuzumab) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
